Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Characterization of an immortalized human small airway basal stem/progenitor cell line with airway region-specific differentiation capacity.

Wang G, Lou HH, Salit J, Leopold PL, Driscoll S, Schymeinsky J, Quast K, Visvanathan S, Fine JS, Thomas MJ, Crystal RG.

Respir Res. 2019 Aug 23;20(1):196. doi: 10.1186/s12931-019-1140-9.

2.

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.

Visvanathan S, Daniluk S, Ptaszyński R, Müller-Ladner U, Ramanujam M, Rosenstock B, Eleftheraki AG, Vinisko R, Petříková A, Kellner H, Dokoupilova E, Kwiatkowska B, Alten R, Schwabe C, Baum P, Joseph D, Fine JS, Padula SJ, Steffgen J.

Ann Rheum Dis. 2019 Jun;78(6):754-760. doi: 10.1136/annrheumdis-2018-214729. Epub 2019 Mar 22.

3.

Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.

Visvanathan S, Baum P, Vinisko R, Schmid R, Flack M, Lalovic B, Kleiner O, Fuentes-Duculan J, Garcet S, Davis JW, Grebe KM, Fine JS, Padula SJ, Krueger JG.

J Allergy Clin Immunol. 2019 Jun;143(6):2158-2169. doi: 10.1016/j.jaci.2018.11.042. Epub 2018 Dec 20.

4.

Differences in Peripheral and Tissue Immune Cell Populations Following Haematopoietic Stem Cell Transplantation in Crohn's Disease Patients.

Corraliza AM, Ricart E, López-García A, Carme Masamunt M, Veny M, Esteller M, Mayorgas A, Le Bourhis L, Allez M, Planell N, Visvanathan S, Baum P, España C, Cabezón-Cabello R, Benítez-Ribas D, Rovira M, Panés J, Salas A.

J Crohns Colitis. 2019 Apr 26;13(5):634-647. doi: 10.1093/ecco-jcc/jjy203.

5.

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO.

Lancet Gastroenterol Hepatol. 2018 Oct;3(10):671-680. doi: 10.1016/S2468-1253(18)30233-4. Epub 2018 Jul 25.

6.

Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.

Visvanathan S, Baum P, Salas A, Vinisko R, Schmid R, Grebe KM, Davis JW, Wallace K, Böcher WO, Padula SJ, Fine JS, Panés J.

J Crohns Colitis. 2018 Nov 9;12(10):1170-1179. doi: 10.1093/ecco-jcc/jjy099.

7.

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ.

Ann Rheum Dis. 2018 Sep;77(9):1295-1302. doi: 10.1136/annrheumdis-2018-213328. Epub 2018 Jun 26.

8.

Ambient Pollution-related Reprogramming of the Human Small Airway Epithelial Transcriptome.

O'Beirne SL, Shenoy SA, Salit J, Strulovici-Barel Y, Kaner RJ, Visvanathan S, Fine JS, Mezey JG, Crystal RG.

Am J Respir Crit Care Med. 2018 Dec 1;198(11):1413-1422. doi: 10.1164/rccm.201712-2526OC.

PMID:
29897792
9.

Accidental Hypothermia Cardiac Arrest Treated Successfully with Invasive Body Cavity Lavage.

Tan JL, Saks M, DelCollo JM, Paryavi M, Visvanathan S, Geller C.

QJM. 2018 Apr 6. doi: 10.1093/qjmed/hcy075. [Epub ahead of print] No abstract available.

PMID:
29660066
10.

Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis.

Planell N, Masamunt MC, Leal RF, Rodríguez L, Esteller M, Lozano JJ, Ramírez A, Ayrizono MLS, Coy CSR, Alfaro I, Ordás I, Visvanathan S, Ricart E, Guardiola J, Panés J, Salas A.

J Crohns Colitis. 2017 Oct 27;11(11):1335-1346. doi: 10.1093/ecco-jcc/jjx091.

11.

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.

Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ.

N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017.

12.

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO.

Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12.

13.

Persistence of circulating endothelial microparticles in COPD despite smoking cessation.

Strulovici-Barel Y, Staudt MR, Krause A, Gordon C, Tilley AE, Harvey BG, Kaner RJ, Hollmann C, Mezey JG, Bitter H, Pillai SG, Hilton H, Wolff G, Stevenson CS, Visvanathan S, Fine JS, Crystal RG.

Thorax. 2016 Dec;71(12):1137-1144. doi: 10.1136/thoraxjnl-2015-208274. Epub 2016 Jul 26.

14.

Misfolded N-CoR is Linked to the Ectopic Reactivation of CD34/Flt3-Based Stem-Cell Phenotype in Promyelocytic and Monocytic Acute Myeloid Leukemia.

Nin DS, Li F, Visvanathan S, Khan M.

Front Oncol. 2015 Oct 7;5:210. doi: 10.3389/fonc.2015.00210. eCollection 2015.

15.

Persistence of smoking-induced dysregulation of miRNA expression in the small airway epithelium despite smoking cessation.

Wang G, Wang R, Strulovici-Barel Y, Salit J, Staudt MR, Ahmed J, Tilley AE, Yee-Levin J, Hollmann C, Harvey BG, Kaner RJ, Mezey JG, Sridhar S, Pillai SG, Hilton H, Wolff G, Bitter H, Visvanathan S, Fine JS, Stevenson CS, Crystal RG.

PLoS One. 2015 Apr 17;10(4):e0120824. doi: 10.1371/journal.pone.0120824. eCollection 2015.

16.

Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.

Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, Lalovic B, Aslanyan S, Wang EE, Hall D, Solinger A, Padula S, Scholl P.

J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7. doi: 10.1016/j.jaci.2015.01.018. Epub 2015 Mar 11.

PMID:
25769911
17.

Intraflagellar transport gene expression associated with short cilia in smoking and COPD.

Hessel J, Heldrich J, Fuller J, Staudt MR, Radisch S, Hollmann C, Harvey BG, Kaner RJ, Salit J, Yee-Levin J, Sridhar S, Pillai S, Hilton H, Wolff G, Bitter H, Visvanathan S, Fine J, Stevenson CS, Crystal RG, Tilley AE.

PLoS One. 2014 Jan 20;9(1):e85453. doi: 10.1371/journal.pone.0085453. eCollection 2014.

18.

Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.

Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agustí A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG; TESRA and ECLIPSE Investigators.

Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57. doi: 10.1164/rccm.201302-0247OC.

PMID:
23947473
19.

Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma.

Desai D, Gupta S, Siddiqui S, Singapuri A, Monteiro W, Entwisle J, Visvanathan S, Parmar H, Kajekar R, Brightling CE.

Respir Res. 2013 Feb 11;14:17. doi: 10.1186/1465-9921-14-17.

20.

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab.

Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, Murphy FT, Papp K, Gomez-Reino JJ, Mack M, Beutler A, Gladman D, Kavanaugh A.

Ann Rheum Dis. 2013 Jan;72(1):83-8. doi: 10.1136/annrheumdis-2012-201697. Epub 2012 Sep 12.

21.

Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity.

Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H, Kourteva G, Bitter H, Pillai SG, Visvanathan S, Müller KC, Holz O, Magnussen H, Watz H, Fine JS.

PLoS One. 2012;7(6):e38629. doi: 10.1371/journal.pone.0038629. Epub 2012 Jun 12.

22.

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.

Wagner C, Visvanathan S, Braun J, van der Heijde D, Deodhar A, Hsu B, Mack M, Elashoff M, Inman RD.

Ann Rheum Dis. 2012 May;71(5):674-80. doi: 10.1136/ard.2010.148890. Epub 2011 Oct 28.

23.

Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.

Visvanathan S, Rahman MU, Hoffman GS, Xu S, García-Martínez A, Segarra M, Lozano E, Espígol-Frigolé G, Hernández-Rodríguez J, Cid MC.

Rheumatology (Oxford). 2011 Nov;50(11):2061-70. doi: 10.1093/rheumatology/ker163. Epub 2011 Aug 25.

24.

Desmoplastic small round cell tumor of the pancreas: An unusual primary site for an uncommon tumor.

Qureshi SS, Shrikhande S, Ramadwar M, Desai S, Visvanathan S, Medhi SS, Laskar S, Muckaden MA, Pai SK, Desai S, Kurkure PA.

J Indian Assoc Pediatr Surg. 2011 Apr;16(2):66-8. doi: 10.4103/0971-9261.78135.

25.

HOPE-BAL: improved molecular diagnostics by application of a novel technique for fixation and paraffin embedding.

Marwitz S, Abdullah M, Vock C, Fine JS, Visvanathan S, Gaede KI, Hauber HP, Zabel P, Goldmann T.

J Histochem Cytochem. 2011 Jun;59(6):601-14. doi: 10.1369/0022155411404417. Epub 2011 Mar 23.

26.

Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.

Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Mack M, Buchanan J, Elashoff M, Wagner C.

Arthritis Res Ther. 2010;12(6):R211. doi: 10.1186/ar3188. Epub 2010 Nov 17.

27.

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial.

Visvanathan S, Wagner C, Marini JC, Lovell DJ, Martini A, Petty R, Cuttica R, Woo P, Espada G, Gattorno M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Quartier P, Saurenmann R, Travers S, Mendelsohn A, Xu S, Giannini EH, Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).

Pediatr Rheumatol Online J. 2010 Sep 7;8:24. doi: 10.1186/1546-0096-8-24.

28.

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, Xu S, Shen YK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).

Ann Rheum Dis. 2010 Apr;69(4):718-22. doi: 10.1136/ard.2009.100354. Erratum in: Ann Rheum Dis. 2011 Nov;70(11):2060. Ann Rheum Dis. 2012 Jun;71(6):1106.

29.

Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab.

Braun J, van der Heijde D, Doyle MK, Han C, Deodhar A, Inman R, de Vlam K, Burmester GR, Van den Bosch F, Xu S, Visvanathan S, Rahman MU.

Arthritis Rheum. 2009 Aug 15;61(8):1032-6. doi: 10.1002/art.24865.

30.

Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.

Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU.

Arthritis Rheum. 2009 Aug;60(8):2272-83. doi: 10.1002/art.24638. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

31.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators.

Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26. Erratum in: Lancet. 2009 Oct 24;374(9699):1422.

PMID:
19560810
32.

E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.

Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU.

J Rheumatol. 2009 Jul;36(7):1371-9. doi: 10.3899/jrheum.080755. Epub 2009 Jun 1. Erratum in: J Rheumatol. 2011 Jan;38(1):183.

PMID:
19487269
33.

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A.

Arthritis Rheum. 2009 Apr;60(4):976-86. doi: 10.1002/art.24403. Erratum in: Arthritis Rheum.2010 Aug;62(8):2555.

34.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU; GO-FORWARD Study.

Ann Rheum Dis. 2009 Jun;68(6):789-96. doi: 10.1136/ard.2008.099010. Epub 2008 Dec 9. Erratum in: Ann Rheum Dis. 2011 Jan;70(1):238.

35.

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

Inman RD, Davis JC Jr, Heijde Dv, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J.

Arthritis Rheum. 2008 Nov;58(11):3402-12. doi: 10.1002/art.23969.

36.

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.

Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.

Arthritis Rheum. 2008 Sep 15;59(9):1270-8. doi: 10.1002/art.24001.

37.

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.

Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J.

Ann Rheum Dis. 2009 Feb;68(2):175-82. doi: 10.1136/ard.2007.084426. Epub 2008 May 21.

38.

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.

Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU.

Arthritis Rheum. 2008 Apr;58(4):964-75. doi: 10.1002/art.23383. Erratum in: Arthritis Rheum. 2010 Nov;62(11):3518.

39.

Anti-TNF antibodies: lessons from the past, roadmap for the future.

Shealy DJ, Visvanathan S.

Handb Exp Pharmacol. 2008;(181):101-29. Review.

PMID:
18071943
40.

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group.

Arthritis Rheum. 2007 Sep;56(9):3096-106.

41.

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.

Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J.

Ann Rheum Dis. 2008 Apr;67(4):511-7. Epub 2007 Jul 20.

42.

Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.

Visvanathan S, Marini JC, Smolen JS, Clair EW, Pritchard C, Shergy W, Pendley C, Baker D, Bala M, Gathany T, Han J, Wagner C.

J Rheumatol. 2007 Jul;34(7):1465-74. Epub 2007 Jun 1.

PMID:
17552048
43.

Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.

Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU; Infliximab-GCA Study Group.

Ann Intern Med. 2007 May 1;146(9):621-30.

PMID:
17470830
44.

Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.

Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL.

J Rheumatol. 2007 May;34(5):952-7. Epub 2007 Apr 15.

PMID:
17444589
45.

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.

Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O.

Ann Rheum Dis. 2007 Jul;66(7):893-9. Epub 2007 Apr 5.

46.

Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.

Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J.

J Rheumatol. 2007 Mar;34(3):510-5. Epub 2007 Feb 1.

PMID:
17299842
47.

IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.

Visvanathan S, Wagner C, Smolen J, St Clair EW, Hegedus R, Baker D, Keenan G.

Arthritis Rheum. 2006 Sep;54(9):2840-4.

48.

Septic arthritis of the hip complicating osteomyelitis of the ischium.

Nouh F, Visvanathan S, Mourad MS, Konidaris G, Van der Wall H, Bruce WM.

Clin Nucl Med. 2004 Sep;29(9):552-3. No abstract available.

PMID:
15311122
49.

Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome.

Visvanathan S, Scott JK, Hwang KK, Banares M, Grossman JM, Merrill JT, FitzGerald J, Chukwuocha RU, Tsao BP, Hahn BH, Chen PP.

Arthritis Rheum. 2003 Mar;48(3):737-45.

50.

Molecular and genetic characterizations of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies.

Chukwuocha RU, Zhu M, Cho CS, Visvanathan S, Hwang KK, Rahman A, Chen PP.

Mol Immunol. 2002 Oct;39(5-6):299-311.

PMID:
12220888

Supplemental Content

Loading ...
Support Center